Replies to post #249135 on Biotech Values

[dewophile]

If any one of Covid PI, Paxlovid patent case or RSV work out it still could be a 90-100 dollar stock (or more). Hindsight is 20/20. We’re talking about the floor for the stock now if things don’t work out w the pipeline in 6-9 months and management shuts things down like they should if there are no viable clinical stage assets left